Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Sorafenib may not be a candidate for use as a posttreatment agent after lenvatinib, according to the results of the present study. Regorafenib has the potential to become an appropriate posttreatment agent after lenvatinib.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Children | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology